DYNAMICS OF BLOOD LIPID INDICATORS AND INFLAMMATORY MARKERS DURING BASIC THERAPY WITH ROSUVASTATIN IN EARLY RHEUMATOID ARTHRITIS
Keywords:
Keywords: early rheumatoid arthritis, atherosclerosis, basic therapy, leflunomide, rosuvastatin, atherogenic dyslipidemia, inflammatory markers.Abstract
Objective: To evaluate blood lipid metabolism disorders, systemic inflammatory markers, and
clinical outcomes in patients with early rheumatoid arthritis (RA) receiving basic disease-modifying
antirheumatic therapy combined with rosuvastatin over a 12-month follow-up period. Materials and
Methods: A prospective, open-label comparative clinical study was conducted enrolling 80 adult
patients aged 18–60 years with confirmed early RA (2010 ACR/EULAR classification criteria).
Patients were randomized into two parallel groups (n = 40 each). Group I received basic diseasemodifying monotherapy with oral leflunomide (20 mg/day). Group II received oral leflunomide (20
mg/day) combined with rosuvastatin (20 mg/day). Clinical disease activity (DAS-28-ESR), pain
severity (VAS 0–100 mm), functional disability (HAQ-DI), serum acute-phase reactants (CRP, ESR),
immunological markers (RF, anti-CCP), and full lipid profiles—total cholesterol (TC), triglycerides
(TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDLC)—were assessed at baseline, 6 months, and 12 months
References
References
1. Abdullaev AX, Alyavi BA, Karimov MM, et al. Lipid metabolism disorders and functional state of
the liver after stenting in patients with ischemic heart disease. Cardiology of Uzbekistan.
2018;48(2):118–119.
2. Antipova VN, Yashina MN. Cardiovascular pathology in rheumatic diseases (literature review). In:
Proceedings of the XLII Ogarev Readings Scientific Conference: Natural Sciences. 2014:158–164.
3. Eliseev MS, Zhelyabina OV, Chikina MN, et al. Effect of therapy on subclinical carotid
atherosclerosis in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis
(pilot study). Rheumatology Science and Practice. 2021;59(6):708–714.
4. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease
prevention in clinical practice. Russ J Cardiol. 2017;(6):7–85.
5. Nasonov EL, Rybakova VV, Avdeeva AS, Dibrov DA. Long-term outcomes of intensive therapy for
early rheumatoid arthritis at disease onset (data from the Russian OREL registry). Rheumatology
Science and Practice. 2021;59(3):269–274.
6. Nasonov EL, Popkova TV. Cardiovascular problems in rheumatology. Rheumatology Science and
Practice. 2004;(4):4–9.
7. Sagitova ER. The role of arterial hypertension in the development of carotid zone changes in patients
with rheumatoid arthritis. In: II All-Russian Congress of Rheumatologists of Russia. 2011:87.
8. Starodubova YN, Osipova IV. Atherosclerosis and systemic inflammation. Scientific and Practical
Journal (Moscow). 2017;13(3):33–42.
9. Tutunov VS, Zubareva MY, Malyshev PP, Kukharchuk VV. Statins in rheumatology. Cardiology
Bulletin (Moscow). 2015;13(3):43–45.
